AI Stock Memo: AMGN - Amgen - RankAlpha

AMGN

AI Memo

Amgen

As of 2026-01-23/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-23 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Late-stage readouts & regulatory milestones • 2027-01-23

Expected move: -1%

Biggest risk

Bear: trial failures, accelerated biosimilar erosion, or adverse pricing/regulatory moves compress revenue and push valuation toward analyst lows.

Invalidation

Break below $180 or thesis failure.

What would change my mind?

Bull: successful late-stage readouts, stable biologics demand, and continued buybacks drive EPS and multiple expansion toward the analyst high.

Research note

Recommendation

—

Confidence

medium

As of

2026-01-23

Base target

$334

p=60%

Bull target

$425

p=20%

Bear target

$180

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

FY2025 Q4 earnings & guidance
Capital-allocation update (buybacks/dividend)
Bull: successful late-stage readouts, stable biologics demand, and continued buybacks drive EPS and multiple expansion toward the analyst high.

BearKey bullets

Biosimilar competition driving pricing/volume erosion
Disappointing capital-allocation actions or integration outcomes
Material guidance or earnings miss

WatchKey bullets

Late-stage readouts & regulatory milestones

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $334 (p=60%)

Bull/Bear spread: +26% / -47%

Vs latest close: Bull +26% · Base -1% · Bear -47%

Scenario probabilities

Bull Target: $425 (p=20%)Base Target: $334 (p=60%)Bear Target: $180 (p=20%)

Commentary

Market tone is mixed: consensus median near $333.98 with a wide spread (low $180 to high $425), indicating divergent views on pipeline and biosimilar risk. Near-term sensitivity centers on the upcoming earnings window and late-stage readouts.

As of 2026-01-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bull: successful late-stage readouts, stable biologics demand, and continued buybacks drive EPS and multiple expansion toward the analyst high.

Bear Case

Bear: trial failures, accelerated biosimilar erosion, or adverse pricing/regulatory moves compress revenue and push valuation toward analyst lows.

Drivers

Scannable catalysts and supporting factors

FY2025 Q4 earnings & guidance
Capital-allocation update (buybacks/dividend)

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-23Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$333.98

Range (USD)

$180.00 - $425.00

Count

Query: Amgen Inc Common (AMGN) analyst consensus price target high low average

Amgen Inc. Analyst Estimates - AMGN - MarketWatch
Search result #1
Stock Price Targets. High, $425.00. Median, $330.00. Low, $215.00. Average, $336.96. Current Price, $331.00. Yearly Numbers. Estimates. AMGN will report 2025 ...
Extracted: $425.00, $330.00, $215.00, $336.96, $331.00Open source
What is the current Price Target and Forecast for Amgen (AMGN)
Search result #2
The forecasts range from a low of $180.00 to a high of $425.00. The average price target represents a decline of 2.86% from the last closing price of $343.60.
Extracted: $180.00, $425.00, $343.60Open source
Amgen (AMGN) Stock Forecast and Price Target 2026 - MarketBeat
Search result #3
According to the 23 analysts' twelve-month price targets for Amgen, the average price target is $339.24. The highest price target for AMGN is $425.00, while the ...
Extracted: $339.24, $425.00Open source
AMGN | Amgen Inc. Analyst Estimates & Ratings – WSJ
Search result #4
Stock Price Target AMGN. High, $425.00. Median, $330.00. Low, $215.00. Average, $336.96. Current Price, $347.07. Related Links: Options · Overview · Research & ...
Extracted: $425.00, $330.00, $215.00, $336.96, $347.07Open source
Amgen Inc.: Target Price Consensus and Analysts Recommendations
Search result #5
Spread / Average Target. -4.46%. High Price Target. 425.00USD. Spread / Highest target. +22.45%. Low Price Target. 180.00USD. Spread / Lowest Target. -48.14% ...
Extracted: $425.00, $180.00Open source
AMGN Stock Quote Price and Forecast - CNN
Search result #6
AMGN is trading near the top of its 52-week range and above its 200-day simple moving average. ... The price of AMGN shares has increased $4.68 since the market ...
Extracted: $4.68Open source

Scenarios

Bull Target (Scenario probability)

$425 / p=20% prob

Base Target (Scenario probability)

$334 / p=60% prob

Bear Target (Scenario probability)

$180 / p=20% prob

Price $336 as of 2026-05-28

Nearest Scenario: Base (∆ 1%)

Targets vs latest close: Bull +26% · Base -1% · Bear -47%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2027-01-23
Late-stage readouts & regulatory milestones
Potential late-stage trial readouts or FDA/EMA decisions; approvals lift value, failures or delays are negative.
Prob 30.00% • Move 18.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

FY2025 Q4 earnings & guidance
2026-04-23
Quarterly results and guidance update; market sensitivity to revenue, biologics demand, and buyback commentary.
Prob 60% • Move 6% • Priced-in 40%
Capital-allocation update (buybacks/dividend)
2026-04-23
Management announcements on buybacks or dividend policy can re-rate shares and shift investor expectations.
Prob 25% • Move 4% • Priced-in 30%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Biosimilar competition driving pricing/volume erosion
Disappointing capital-allocation actions or integration outcomes
Material guidance or earnings miss
Negative late-stage trial or regulatory outcomes

Peers

Symbol	Summary
GILD	Large biotech with significant commercial/regulatory risk exposure; useful for biologics commercialization comparison.
ABBV	Major biologics and immunology franchise; comparable revenue stability and patent-timing risk.
BMY	Integrated pharma with oncology footprint; helpful comparator on diversification and pricing exposure.
REGN	Biotech focused on antibody therapeutics; aligns with Amgen on late-stage readout sensitivity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Amgen Inc Common (AMGN) analyst consensus price target high low average
Analysis date: 2026-01-23